DONATE

New technology for mass serological analysis

A study by Stanford University and the Institute for Bioengineering of Catalonia describes an innovative technology that enables the large-scale analysis of antibodies in biological samples. Using microscopic beads marked with stable isotopes, this advance surpasses traditional techniques, accelerating the study of immune responses and opening up new possibilities for biomedical research.

Bist Career Week 2025

Join the BIST Career Week! 5 days full of contents designed to help you in your career development. Learn trips and tricks in the morning, and explore new job opportunities … Read more

IBEC co-organises Europe’s largest nanomedicine event to mark the 20th anniversary of NANOMED Spain and ETPN

The NanoMed Europe 2025 conference, Europe’s leading event in the field of nanomedicine and advanced health technologies, took place from 27 to 30 May. This edition was hosted in Barcelona, coinciding with the 20th anniversary of the Spanish Nanomedicine Platform (NANOMED Spain), which is coordinated by the Institute for Bioengineering of Catalonia (IBEC). Since its establishment in 2005, NANOMED Spain has collaborated closely with the European Technology Platform for Nanomedicine (ETPN) to encourage nanomedicine innovation in Spain and across Europe.

Disrupting malaria’s inner balance: targeting parasite’s protein control system could be key to innovative treatments

IBEC and ISGlobal researchers led a study that points towards protein aggregation as a possible target to find new ways to reduce the viability of Plasmodium falciparum, the main causing agent of malaria. By inducing protein aggregation, they observed considerable disorders in protein homeostasis and a significant reduction in parasite growth. The results position protein aggregation control as a promising target for antimalarial therapies.

IBEC receives funding from the prestigious Human Frontier Science Program

Illustration of a human cancer cell

The Institute for Bioengineering of Catalonia (IBEC) is participating in the international SOLFEGE project, which aims to explore how different cell types coordinate with each other through soluble factors in the tumour microenvironment. This project has been made possible thanks to funding from the Human Frontier Science Program. SOLFEGE is a consortium led by the German Cancer Research Center (DKFZ), with IBEC and the Duke University, as partners.